Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma

Clinical Epigenetics

Andreas K. Nussler⁶  Bence Sipos²  Hossein Baharvand⁴  Steven Dooley⁷  Wolfgang Thasler⁵  Daniel Seehofer³  Georg Damm³  Eirini Koutsouraki¹  Haghighat Vakilian⁴  Sabrina Ehnert⁶  Sahar Olsadat Sajadian⁶ 

[1] Centre for Clinical Brain Sciences, Chancellor’s Building 49 Little France Crescent, Edinburgh, UK;Department of Pathology, Eberhard-Karls University Tübingen, Tübingen, Germany;Department of General Surgery, Universitätsmedizin Berlin, Berlin, Germany;Department of Stem Cells and Developmental Biology at the Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran;Department of General, Visceral, Transplantation, Vascular, and Thoracic Surgery, University of Munich, Campus Grosshadern, Munich, Germany;Eberhard-Karls University Tübingen, BG Trauma Clinic, SWI, Schnarrenbergstraße 95, Tübingen, 72076, Germany;Section Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany

关键词: Cancer biomarker;    5-Azacytidine;    DNA methylation;    5-Hydroxymethylcytosine;    TET;   

Others  :  1225841
DOI  :  10.1186/s13148-015-0133-x

 received in 2015-06-16, accepted in 2015-09-04,  发布年份 2015

【 摘 要 】

Background

Global deregulation of DNA methylation is one of the crucial causes of hepato cellular carcinoma (HCC). It has been reported that the anti-cancer drug 5-azacytidine (5-AZA) mediates the activation of tumor suppressor genes through passive demethylation by inhibiting DNMT1. Recent evidence suggests that active demethylation which is mediated by ten-eleven translocation (TET) proteins may also be an important step to control global methylation. However, there exists a controversial discussion in which TET proteins are involved in the demethylation process in HCC. Therefore, we firstly wanted to identify which of the TETs are involved in demethylation and later to study whether or not 5-AZA could trigger the TET-dependent active demethylation process in HCC. HCC cell lines (Huh-7, HLE, HLF), primary human hepatocytes (hHeps), and tissues from both healthy (55 patients) and HCC patients (55 patients) were included in this study; mRNA levels of isocitrate dehydrogenase (IDH1, 2) and TETs (TET1–3) were studied via qPCR and confirmed by Western blot. The expression of 5hmC/5mC was determined by immunohistochemistry in human HCC tissues and the corresponding adjacent healthy liver. HCC cell lines were stimulated with 5-AZA (0–20 μM) and viability (Resazurin conversion), toxicity (LDH release), proliferation (PCNA), and 5hmC/5mC distribution were assessed. In addition, knockdown experiments on TET proteins in HCC cell lines using short interference RNAs (siRNAs), in the presence and absence of 5-AZA, were performed.

Results

Our data applying qPCR, immunofluorescence, and Western blotting clearly show that TET2 and TET3 but not TET1 were significantly decreased in HCC tissue and different HCC cell lines compared to non-tumor liver tissues and hHeps. In addition, we show here for the first time applying knockdown experiments that 5-AZA is able to trigger an active TET2-dependent demethylation process with concomitant significant changes in 5hmC/5mC in HCC cell lines and hHeps.

Conclusions

Our data clearly show that the expression and activity of TET2 and TET3 proteins but not TET1 are impaired in hepatocellular carcinoma leading to the reduction of 5hmC in HCCs. Furthermore, this study identified a novel function of 5-azacytidine in promoting a TET-mediated generation of 5hmC suggesting that the availability of 5-AZA in cancer cells will have various effects on different epigenetic targets. These findings may open new therapeutic strategies for epigenetic drugs to treat HCC.

【 授权许可】

   
2015 Sajadian et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3(4):253-66.
• [2]Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999, 23(2):185-8.
• [3]Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-28.
• [4]Baylin SB: Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science 1997, 277(5334):1948-9.
• [5]Costello JF, Plass C: Methylation matters. J Med Genet 2001, 38(5):285-303.
• [6]Das PM, Singal R: DNA methylation and cancer. J Clin Oncol 2004, 22(22):4632-42.
• [7]Bestor T, Laudano A, Mattaliano R, Ingram V: Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells: the carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 1988, 203(4):971-83.
• [8]Wu H, Zhang Y: Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 2011, 25(23):2436-52.
• [9]Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al.: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-5.
• [10]Kohli RM, Zhang Y: TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013, 502(7472):472-9.
• [11]Guo JU, Su Y, Zhong C: Ming G-l, Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 2011, 10(16):2662-8.
• [12]Wu SC, Zhang Y: Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010, 11(9):607-20.
• [13]Surani M, Hajkova P, editors. Epigenetic reprogramming of mouse germ cells toward totipotency. Cold Spring Harbor Symposia on Quantitative Biology; 2010: Cold Spring Harbor Laboratory Press. doi:10.1101/sqb.2010.75.010.
• [14]Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y: Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466(7310):1129-33.
• [15]Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al.: Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333(6047):1300-3.
• [16]Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al.: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150(6):1135-46.
• [17]Delhommeau F, Dupont S, Valle VD, James C, Trannoy S, Masse A, et al.: Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(22):2289-301.
• [18]Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, et al.: Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One 2013, 8(5):e62828.
• [19]Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al.: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41(7):838-42.
• [20]Dang L, Jin S, Su SM: IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010, 16(9):387-97.
• [21]Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C: Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One 2011, 6(5):e19868.
• [22]Bruix J, Boix L, Sala M, Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 2004, 5(3):215-9.
• [23]Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-90.
• [24]Nishida N, Goel A: Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 2011, 12(2):130.
• [25]Anwar SL, Lehmann U: DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol 2014, 20(24):7894.
• [26]Gao F, Xia Y, Wang J, Lin Z, Ou Y, Liu X, et al.: Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of ECM1, ATF5, and EOMES in human hepatocellular carcinoma. Genome Biol 2014, 15(12):533. BioMed Central Full Text
• [27]Yang H, Liu Y, Bai F, Zhang J, Ma S, Liu J, et al.: Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32(5):663-9.
• [28]Griffiths EA, Gore SD, editors. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in hematology; 2008;45(1):23–30.
• [29]Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al.: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66(12):6361-9.
• [30]Nussler AK, Nussler NC, Merk V, Brulport M, Schormann W, Yao P, et al.: The holy grail of hepatocyte culturing and therapeutic use. In Strategies in regenerative medicine. Edited by Santin M. Springer, New York; 2009:1-38.
• [31]Dzieran J, Fabian J, Feng T, Coulouarn C, Ilkavets I, Kyselova A, et al.: Comparative analysis of TGF-β/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines. PLoS One 2013, 8(8):e72252.
• [32]Lin J, Schyschka L, Mühl-Benninghaus R, Neumann J, Hao L, Nussler N, et al.: Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism. Arch Toxicol 2012, 86(1):87-95.
• [33]Liu W-R, Tian M-X, Jin L, Yang L-X, Ding Z-B, Shen Y-H, et al.: High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. J Exp Clin Cancer Res 2014, 33(1):1-9. BioMed Central Full Text
• [34]Polzer H, Haasters F, Prall WC, Saller MM, Volkmer E, Drosse I, et al.: Quantification of fluorescence intensity of labeled human mesenchymal stem cells and cell counting of unlabeled cells in phase-contrast imaging: an open-source-based algorithm. Tissue Eng Part C Methods 2010, 16(6):1277-85.
• [35]Waxman S, Wurmbach E: De-regulation of common housekeeping genes in hepatocellular carcinoma. BMC Genomics 2007, 8(1):243. BioMed Central Full Text
• [36]Riccardi C, Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006, 1(3):1458-61.
• [37]Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, et al.: Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2(8):627.
• [38]Waseem NH, Lane DP: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 1990, 96(1):121-9.
• [39]Jones P, Taylor S, Wilson V: Inhibition of DNA methylation by 5-azacytidine. In Modified nucleosides and cancer. Edited by Nass G. Springer, New York; 1983:202-11.
• [40]Yan X, Ehnert S, Culmes M, Bachmann A, Seeliger C, Schyschka L, et al.: 5-Azacytidine improves the osteogenic differentiation potential of aged human adipose-derived mesenchymal stem cells by DNA demethylation. PLoS One 2014, 9(3):e90846.
• [41]Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-59.
• [42]Kroeze LI, van der Reijden BA, Jansen JH. 5-hydroxymethylcytosine: an epigenetic mark frequently deregulated in cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2015.
• [43]Huang Y, Rao A: Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 2014, 30(10):464-74.
• [44]Wang J, Tang J, Lai M, Zhang H: 5-Hydroxymethylcytosine and disease. Mutation Research/Reviews in Mutation Research 2014, 762:167-75.
• [45]Tan L, Shi YG: Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 2012, 139(11):1895-902.
• [46]Ivanov M, Kals M, Kacevska M, Barragan I, Kasuga K, Rane A, et al.: Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol 2013, 14(8):R83. BioMed Central Full Text
• [47]Seeliger C, Culmes M, Schyschka L, Yan X, Damm G, Wang Z, et al.: Decrease of global methylation improves significantly hepatic differentiation of Ad-MSCs: possible future application for urea detoxification. Cell Transplant 2013, 22(1):119-31.
• [48]Baylin SB, Jones PA: A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 2011, 11(10):726-34.
• [49]Khan O, La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2011, 90(1):85-94.
• [50]He Y-F, Li B-Z, Li Z, Liu P, Wang Y, Tang Q, et al.: Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333(6047):1303-7.
• [51]Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, et al.: Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011, 42(4):451-64.
• [52]Hsu C-H, Peng K-L, Kang M-L, Chen Y-R, Yang Y-C, Tsai C-H, et al.: TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Reports 2012, 2(3):568-79.
• [53]Necula LG, Mambet C, Albulescu R, Diaconu CC: Epigenetics in gastric carcinogenesis: Tet genes as important players. J Immunoass Immunochem 2015, 36(5):445-55.
• [54]Ye D, Ma S, Xiong Y, Guan K-L: R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell 2013, 23(3):274-6.
• [55]Tarayrah L, Chen X: Epigenetic regulation in adult stem cells and cancers. Cell Biosci 2013, 3(1):41. BioMed Central Full Text
• [56]Christman JK: 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21(35):5483-95.